(NASDAQ:HQY), DRAPER, Utah, Nov. 05, 2025 (GLOBE NEWSWIRE) — HealthEquity, Inc. (NASDAQ: HQY) (“HealthEquity” or the “Company”), the nation's largest Health Savings Accounts (“HSA”) and consumer-directed benefits administrator, today announced plans to release financial results of its third quarter of fiscal 2026 following the close of regular stock market trading hours on Wednesday, December 3, […]
(NasdaqGM:RYTM), BOSTON, Nov. 05, 2025 (GLOBE NEWSWIRE) — Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases, today announced that it has entered into Product Listing Agreements in the provinces of Ontario, Alberta, British Columbia, Saskatchewan, Nova Scotia and with the Federal
(NASDAQ:XFOR), BOSTON, Nov. 05, 2025 (GLOBE NEWSWIRE) — X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare hematology diseases, today announced that the management team will participate in the upcoming Guggenheim Second Annual Healthcare Innovation Conference on November 10-12, 2025 in Boston. The X4 team will hold a fireside
(NASDAQ:SNDX), NEW YORK, Nov. 05, 2025 (GLOBE NEWSWIRE) — Syndax Pharmaceuticals (Nasdaq: SNDX), a commercial-stage biopharmaceutical company advancing innovative cancer therapies, today announced that on November 1, 2025, the Company granted inducement awards to purchase up to 143,500 shares of common stock to four new employees under the Company's 2023 Inducement Plan. The stock options
(Brussels:GLPG),(Euronext Amsterdam:GLPG), Strategic review process concluded with intention to wind down cell therapy business, representing optimal capital allocation pathway to support a stronger and sustainable future for Galapagos Continued evolution of leadership team aligned with strategic direction Robust balance sheet with EUR3.05 billion in cash and financial investments as of September 30, 2025; year-end 2025
Ascendis Pharma to Report Third Quarter 2025 Financial Results and Provide Business Update on November 12, 2025 GlobeNewswire November 05, 2025 COPENHAGEN, Denmark, Nov. 05, 2025 (GLOBE NEWSWIRE) — Ascendis Pharma A/S (Nasdaq: ASND) today announced it plans to report third quarter 2025 financial results and provide a business update on Wednesday, November 12, 2025,
Aquestive Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Update GlobeNewswire November 05, 2025 Planned U.S. launch of Anaphylm(TM) in the first quarter of 2026, if approved by the FDA Advanced Anaphylm regulatory activities in Canada and the EU Added clinical leadership to drive long-term success Strengthened balance sheet to support planned commercial
LegalZoom Reports Strong Third Quarter 2025 Financial Results, Again Raises 2025 Revenue Growth Expectations GlobeNewswire November 05, 2025 Strong execution with record third quarter revenue exceeding the high end of outlook range Revenue of $190.2 million, up 13% year-over-year Subscription revenue of $125.4 million, an increase of 13% year-over-year, led by growth in our compliance
Praxis Precision Medicines to Participate in Upcoming Investor Conferences GlobeNewswire November 05, 2025 BOSTON, Nov. 05, 2025 (GLOBE NEWSWIRE) — Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation inhibition imbalance, announced it will be attending
Duolingo Surpasses 50 Million Daily Active Users, Grows DAU 36% and Revenue 41% in Third Quarter 2025 Year over Year GlobeNewswire November 05, 2025 PITTSBURGH, Nov. 05, 2025 (GLOBE NEWSWIRE) — Duolingo, Inc. (NASDAQ: DUOL) announced results for the third quarter ended September 30, 2025 in a shareholder letter that is posted on its Investor